High incidence of severe influenza among individuals over 50 years of age

Clinical and Vaccine Immunology

Volumn 18, Issue 11, 2011, Pages 1918-1924

  Zhang, Anna J X ^a   To, Kelvin K W ^a   Tse, Herman ^a   Chan, Kwok Hung ^a   Guo, Kun Yuan ^a   Li, Can ^a   Hung, Ivan F N ^a   Chan, Jasper F W ^a   Chen, Honglin ^a   Tam, Sidney ^b   Yuen, Kwok Yung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFANT; INFECTION RATE; INFECTION RISK; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; RESPIRATORY VIRUS; RISK ASSESSMENT; SEASONAL VARIATION; SEROPREVALENCE; SPECIES COMPARISON; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HONG KONG; HUMANS; INCIDENCE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 80455128645     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05357-11     Document Type: Article

References (54)

1. Adamson, W. E., et al. 2010. 2009 pandemic influenza A(H1N1) virus in Scotland: geographically variable immunity in spring 2010, following the winter outbreak. Euro Surveill. 15:19590.
2. Allwinn, R., J. Geiler, A. Berger, J. Cinatl, and H. W. Doerr. 2010. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med. Microbiol. Immunol. 199:117-121.
3. Baguelin, M., et al. 2011. Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood- based estimation. PLoS One 6:e17074.
4. Bandaranayake, D., et al. 2010. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS One 5:e13211.
5. Broberg, E., A. Nicoll, and A. Amato-Gauci. 2011. Seroprevalence to influenza A(H1N1) 2009 virus-where are we? Clin. Vaccine Immunol. 18:1205-1212.
6. Cao, B., et al. 2009. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N. Engl. J. Med. 361:2507-2517.
7. Chan, K. H., et al. 2011. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin. Vaccine Immunol. 18:867-873.
8. Chan, Y. J., et al. 2010. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. J. Chin. Med. Assoc. 73:62-66.
9. Chen, M. I., et al. 2010. 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 303:1383-1391.
10. Chowell, G., et al. 2011. Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLoS Med. 8:e1000436.
11. Deng, Y., et al. 2011. Serological survey of 2009 H1N1 influenza in residents of Beijing, China. Epidemiol. Infect. 139:52-58.
12. Doherty, P. C., S. J. Turner, R. G. Webby, and P. G. Thomas. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7:449-455.
13. Dominguez-Cherit, G., et al. 2009. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302:1880-1887.
14. Donaldson, L. J., et al. 2009. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339:b5213.
15. Dowse, G. K., et al. 2011. Incidence of pandemic (H1N1) 2009 influenza infection in children and pregnant women during the 2009 influenza season in Western Australia-a seroprevalence study. Med. J. Aust. 194:68-72.
16. Dudareva, S., et al. 2011. Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One 6:e21340.
17. Echevarria-Zuno, S., et al. 2009. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374:2072-2079.
18. Fiore, A. E., et al. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59:1-62.
19. Gilbert, G. L., et al. 2010. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS One 5:e12562.
20. Grills, N., et al. 2010. A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009. Aust. N. Z. J. Public Health 34:228-231.
21. Guo, X., et al. 2011. Dynamic variations in the peripheral blood lymphocyte subgroups of patients with 2009 pandemic H1N1 swine-origin influenza A virus infection. Virol. J. 8:215.
22. Hancock, K., et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952.
23. Hong Kong Government. 2008. Special topics report no. 48. Persons with disabilities and chronic diseases. Census and Statistics Department, Hong Kong, Special Administrative Region, China.
24. Ikonen, N., et al. 2010. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill. 15:19478.
25. Jain, S., et al. 2009. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 361:1935-1944.
26. Jegerlehner, A., N. Schmitz, T. Storni, and M. F. Bachmann. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172:5598-5605. (Pubitemid 38542062)
27. Jhung, M. A., et al. 2011. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin. Infect. Dis. 52(Suppl. 1):S13-S26.
28. Kumar, A., et al. 2009. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302:1872-1879.
29. Lerdsamran, H., et al. 2011. Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population. PLoS One 6:e16164.
30. Louie, J. K., et al. 2009. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302: 1896-1902.
31. Mahmud, S. M., et al. 2010. Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic. CMAJ 182:1522-1524.
32. Mak, G. C., et al. 2010. Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong. J. Med. Virol. 82:1809-1815.
33. McVernon, J., et al. 2010. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October-December 2009. Euro Surveill. 15:7-14.
34. Miller, E., et al. 2010. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375:1100-1108.
35. Moghadami, M., et al. 2010. High titers of hemagglutination inhibition antibodies against 2009 H1N1 influenza virus in Southern Iran. Iran J. Immunol. 7:39-48.
36. Nishiura, H. 2010. Case fatality ratio of pandemic influenza. Lancet Infect. Dis. 10:443-444.
37. Panda, A., et al. 2009. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 30:325-333.
38. Perez-Padilla, R., et al. 2009. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 361:680-689.
39. Ross, T., et al. 2010. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza. PLoS Curr. 2:RRN1148.
40. Rouse, B. T., and S. Sehrawat. 2010. Immunity and immunopathology to viruses: what decides the outcome? Nat. Rev. Immunol. 10:514-526.
41. Skowronski, D. M., et al. 2010. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ 182:1851-1856.
42. Tan, S., et al. 2011. Serological responses following influenza A H1N1 2009 infection in adults. J. Infect. 62:388-393.
43. Tandale, B. V., et al. 2010. Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India. BMC Infect. Dis. 10:255.
44. Tian, L. L., et al. 2011. Serologic survey of pandemic influenza A (H1N1 2009) in Beijing, China. Prev. Med. 52:71-74.
45. To, K. K., et al. 2010. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50:850-859.
46. Tsai, T. F., et al. 2010. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Euro Surveill. 15:19624.
47. Van Kerkhove, M. D., et al. 2011. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 8:e1001053.
48. Webb, S. A., et al. 2009. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N. Engl. J. Med. 361:1925-1934.
49. Woo, P. C., et al. 2004. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet 363:841-845. (Pubitemid 38368831)
50. World Health Organization. 2010. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. WHO, Geneva, Switzerland.
51. Wu, J. T., et al. 2010. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin. Infect. Dis. 51:1184-1191.
52. Yang, P., et al. 2011. Serological surveillance of 2009 H1N1 influenza in China. Int. J. Infect. Dis. 15:e151-e152.
53. Zhou, Y., et al. 2011. Seroprevalence of antibody to pandemic influenza A (H1N1) 2009 among healthcare workers after the first wave in Hong Kong. J. Hosp. Infect. 78:308-311.
54. Zimmer, S. M., et al. 2010. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One 5:e11601.